• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    SC 13G/A 1 d879544dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 1)*

     

     

    Avantor, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    05352A100

    (CUSIP Number)

    July 31, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 05352A100    13G    PAGE 2 OF 4 PAGES

     

     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Dodge & Cox    94-1441976

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     N/A

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     California - U.S.A.

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     65,034,296

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     68,653,796

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     68,653,796

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     N/A

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     10.1%

    12  

     TYPE OF REPORTING PERSON*

     

     IA


    Item 1 (a)

    Name of Issuer:

    Avantor, Inc.

     

    Item 1 (b)

    Address of Issuer’s Principal Executive Offices:

    Radnor Corporate Center, Building One, Suite 200

    100 Matsonford Road

    Radnor, PA 19087

     

    Item 2 (a)

    Name of Person Filing:

    Dodge & Cox

     

    Item 2 (b)

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2 (c)

    Citizenship:

    California - U.S.A.

     

    Item 2 (d)

    Title of Class of Securities:

    Common Stock

     

    Item 2 (e)

    CUSIP Number:

    05352A100

     

    Item 3

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

    (e) ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    68,653,796

     

      (b)

    Percent of Class:

    10.1%

     

    PAGE 3 OF 4 PAGES


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    65,034,296

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of: 68,653,796

     

      (iv)

    shared power to dispose or to direct the disposition of: 0

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, Avantor, Inc.

    Dodge & Cox Stock Fund, an investment company registered under the Investment Company Act of 1940, has an interest of 45,486,043, or 6.7%, of the class of securities reported herein.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

     

    PAGE 4 OF 4 PAGES


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 9, 2024

     

    DODGE & COX
    By:   /S/ Katherine M. Primas
    Name:   Katherine M. Primas
    Title:   Chief Compliance Officer
    Get the next $AVTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    6/2/2026$7.00Underperform
    Wolfe Research
    5/15/2026$9.00Sector Perform
    RBC Capital Mkts
    3/6/2026$8.50Equal Weight → Underweight
    Barclays
    1/5/2026$12.00Outperform → In-line
    Evercore ISI
    12/17/2025$9.00Hold → Underperform
    Jefferies
    12/15/2025$13.00Buy → Neutral
    BofA Securities
    11/4/2025Outperform → Mkt Perform
    Raymond James
    10/30/2025$12.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/11/26 4:39:13 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dingemans Simon bought $203,500 worth of shares (25,000 units at $8.14) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/5/26 7:44:08 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Lucier Gregory T bought $458,000 worth of shares (50,000 units at $9.16) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/23/26 8:53:53 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/11/26 4:39:21 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/11/26 4:39:13 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dingemans Simon was granted 25,270 shares, increasing direct ownership by 406% to 31,495 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/11/26 4:39:05 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    SEC Filings

    View All

    SEC Form SD filed by Avantor Inc.

    SD - Avantor, Inc. (0001722482) (Filer)

    5/29/26 4:06:35 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    5/12/26 4:32:48 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Avantor Inc.

    10-Q - Avantor, Inc. (0001722482) (Filer)

    4/29/26 9:02:03 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Avantor with a new price target

    Wolfe Research resumed coverage of Avantor with a rating of Underperform and set a new price target of $7.00

    6/2/26 8:32:11 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    RBC Capital Mkts resumed coverage on Avantor with a new price target

    RBC Capital Mkts resumed coverage of Avantor with a rating of Sector Perform and set a new price target of $9.00

    5/15/26 8:27:36 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Barclays with a new price target

    Barclays downgraded Avantor from Equal Weight to Underweight and set a new price target of $8.50

    3/6/26 8:24:43 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory

    RADNOR, Pa., May 19, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gerard (Jerry) Porreca has joined the company as Executive Vice President, Quality and Regulatory. In this role, Mr. Porreca is responsible for leading quality assurance, quality systems and regulatory affairs globally across all Avantor's businesses.Mr. Porreca is an accomplished executive with deep quality, regulatory affairs, and compliance experience

    5/19/26 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports First Quarter 2026 Results

    Net sales of $1,581 millionNet income of $43 million; Adjusted EBITDA of $219 millionDiluted GAAP EPS of $0.06; adjusted EPS of $0.17Operating cash flow of $59 million; free cash flow of $25 millionReaffirms FY 2026 guidanceRADNOR, Pa., April 29, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2026."First quarter results exceeded our expectations due to improved execution in Bioscience and Medtech Products, and we saw stabilization in VWR," said Emmanuel Ligner, President and Chi

    4/29/26 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer

    RADNOR, Pa., April 23, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Ludovic Brellier will join the company as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer on May 1, 2026. In this role, Mr. Brellier will be responsible for growing the BMP business and improving operational performance. He will also lead the Revival Management Office, driving transformation initiatives acros

    4/23/26 5:05:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Sanjeev Mehra to its Board of Directors

    RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately.   Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,

    12/4/25 4:15:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

    RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit

    11/10/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® Reports First Quarter 2026 Results

    Net sales of $1,581 millionNet income of $43 million; Adjusted EBITDA of $219 millionDiluted GAAP EPS of $0.06; adjusted EPS of $0.17Operating cash flow of $59 million; free cash flow of $25 millionReaffirms FY 2026 guidanceRADNOR, Pa., April 29, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2026."First quarter results exceeded our expectations due to improved execution in Bioscience and Medtech Products, and we saw stabilization in VWR," said Emmanuel Ligner, President and Chi

    4/29/26 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026

    RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl

    4/3/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Fourth Quarter and Full Year 2025 Results

    Revival program underway, including relaunch of VWR brand, implementation of critical manufacturing and supply chain improvements, and upgrades to e-commerce channel Fourth Quarter 2025 Net sales of $1.66 billion, decrease of 1%; organic decrease of 4%Net income of $52 million; Adjusted EBITDA of $252 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.22Operating cash flow of $153 million; free cash flow of $117 millionFull Year 2025 Net sales of $6.55 billion, decrease of 3%; organic decline of 3%Net loss of $530 million; Adjusted EBITDA of $1,069 millionDiluted GAAP loss per share of $0.78; adjusted EPS of $0.90Operating cash flow of $624 million; free cash flow of $496 millionRADNOR, Pa

    2/11/26 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials